umu.sePublications
Change search
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf
Risk For Low Visual Acuity After 1 And 2 Years Of Treatment With Ranibizumab Or Bevacizumab For Patients With Neovascular Age-Related Macular Degeneration
Umeå University, Faculty of Medicine, Department of Clinical Sciences, Ophthalmology.
2017 (English)In: Retina, ISSN 0275-004X, E-ISSN 1539-2864, Vol. 37, no 11, p. 2035-2046Article in journal (Refereed) Published
Abstract [en]

Purpose: To investigate how patients with neovascular age-related macular degeneration treated with ranibizumab or bevacizumab respond to treatment in daily clinical practice.

Methods: Data from the Swedish Macula Register on the treatment received by 3,912 patients during 2011 to 2014 is reported. Patients' characteristics at the first visit, visual acuity, number of injections, and reason for terminating the treatment if applicable are discussed. Furthermore, the risk of having poor vision (visual acuity under 60 Early Treatment Diabetes Retinopathy Study letters or approximately 20/60 Snellen) is calculated for the treated eye after 1 year and 2 years.

Results: The treatment outcome depends on the visual acuity at the first visit. For patients with visual acuity more than 60 letters, the risk of having a visual acuity lower than 60 letters after 1 year or 2 years of treatment is approximately 20%. However, for patients with low visual acuity at diagnosis (fewer than 60 letters), the risk is approximately 60%. The risk of having a visual acuity lower than 60 letters does not depend on the choice of treatment drug.

Conclusion: Treatment with anti-vascular endothelial growth factor intravitreal injections mainly maintains the visual acuity level, and only approximately 20% and 40% of the patients required vision rehabilitation after 1 year and 2 years, respectively.

Place, publisher, year, edition, pages
Lippincott Williams & Wilkins, 2017. Vol. 37, no 11, p. 2035-2046
Keywords [en]
neovascular age-related macular degeneration, bevacizumab, choroidal neovascularization, ETDRS, nibizumab, register data
National Category
Ophthalmology
Identifiers
URN: urn:nbn:se:umu:diva-145623DOI: 10.1097/IAE.0000000000001431ISI: 000425208800022PubMedID: 28141748OAI: oai:DiVA.org:umu-145623DiVA, id: diva2:1190599
Available from: 2018-03-15 Created: 2018-03-15 Last updated: 2018-06-09Bibliographically approved

Open Access in DiVA

No full text in DiVA

Other links

Publisher's full textPubMed

Authority records BETA

Westborg, IngerRosso, Aldana

Search in DiVA

By author/editor
Westborg, IngerRosso, Aldana
By organisation
Ophthalmology
In the same journal
Retina
Ophthalmology

Search outside of DiVA

GoogleGoogle Scholar

doi
pubmed
urn-nbn

Altmetric score

doi
pubmed
urn-nbn
Total: 51 hits
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf